All In Biotech

Drug Trial Radar · NCT00790062

Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT

Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery

Last checked: Nov 19, 2026Latest source record: Apr 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,798 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,798

Actual

Start

Nov 2008

Primary completion

Jun 2010

Study completion Jun 2010

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.

Conditions

  • Uterine Atony
  • Postpartum Hemorrhage

Interventions

  • OxytocinDrug

    See arms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional TreatmentTime frame: baseline to discharge (2 - 3 days)
  2. Women in Each Group With Risk Factors for Atony or Postpartum HemorrhageTime frame: Initial hospital discharge (2-3 days)
  3. Risk to Using Increasing Doses of Oxytocin Based on Pre-specified Risk FactorsTime frame: baseline to discharge (2-3 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.